moveUP develops data-driven personalized remote digital care for patients undergoing surgery and other interventions.
moveUP has raised €3.65 million in order to continue its success story in Belgium and beyond. The financing round was co-led by Karista (France) and White Fund (Belgium), in an international consortium with Nina Capital (Spain), CAREvolution (Belgium) and Qbic (Belgium), and moveUP’s historical investors. The financing will enable moveUP to further develop its solution and accelerate its international expansion.
Despite the advancements in surgical procedures, a substantial number of patients remain dissatisfied with chronic pain as the most prevalent indication. Patient dissatisfaction goes hand in hand with low patient engagement, leading to a more difficult rehabilitation process and unexpected costs. With its digital solution, moveUP gives patients a personalized, digitally delivered rehabilitation plan, and healthcare providers remote, data-driven insights during the follow-up of their patients. This way, moveUP contributes to a reduced rate of complications, readmissions and hospital stay as well as higher patient satisfaction.
Over the past years, the demand for remote healthcare solutions has continued to rise. Digital, (semi-)automated yet personalised healthcare solutions support practitioners to stay connected to the patient at all times, collect data in a structured way and, in the meantime, focus time and attention on the patients who need it the most. moveUP provides value-based treatment plans on an integrated platform, managed by local care teams and supported 24/7 by b.clinic. This virtual clinic, a subsidiary of moveUP, allows hospitals to outsource part of the post-surgery care in the area of orthopaedics and bariatrics.
Today, moveUP’s application is reimbursed in the area of orthopaedics in Belgium. moveUP is currently reinforcing its presence in the Netherlands, France, Germany and the UK, while exploring the US market. The core platform of moveUP is also used by several major biopharmaceutical and medical device companies as backbone to support the development and delivery of data-driven care pathways. Such partnerships will be amplified and internationalized.
In order to support its growth, moveUP has successfully completed a financing round co-led by Karista and White Fund, in a European consortium with Nina Capital, CAREvolution and Qbic. Early investors, including the Brussels-Capital Region and Sambrinvest, also subscribed to the financing round. The €3.65 million raised adds to the €2.7 million awarded last year by the European Innovation Council (EIC) to further develop and scale moveUP’s value-based healthcare concept in orthopaedics, bariatrics and beyond, both in Europe and the US.
Ward Servaes, co-founder and CEO of moveUP: “Over the past year, we have made enormous progress with our solution. To date, moveUP has guided over 2,000 patients through their hip and knee replacement, both pre- and post-surgery, with high level patient satisfaction and data completeness rates. This investment will now allow us to scale up. On the one hand, we will apply our expertise in other countries. For this, we already started dedicated activities in selected growth countries. On the other hand, we will further invest in our product. This means further applying our value-based healthcare principles in existing therapies while also targeting other therapeutic areas. It has been great to build out our concept in close collaboration with healthcare providers in hospitals, with the highly appreciated support of Belgian and European authorities.”
Baudouin Hue, Partner at Karista: “We are pleased to co-lead this new investment round to support moveUP’s further development. The value of the concept is indisputable for patients, for healthcare providers and for the healthcare system as a whole. To give an idea: the reductions in hospital readmissions, as well as rationalization of rehabilitation and other indirect costs allow to save up to €1,700 per patient on average (15% of the total cost of the procedure), while showing excellent clinical outcomes. As European healthtech specialists, we strongly believe that moveUP is becoming a true game changer, contributing to a more efficient and value-based healthcare system, which we are very proud to support.”
Michel Baijot, Chairman of White Fund: “As a Belgian investment fund dedicated to the medtech sector, we aim to enrich the existing ecosystem by supporting promising projects that have the potential to revolutionise the healthcare sector. We co-lead this investment round of moveUP as the company’s focus is to deliver better clinical outcomes at a lower cost, leading to a better pre- and post-surgery experience and patient satisfaction. We look forward to sharing our expertise with moveUP’s team in order to further develop this clinically validated solution, both in Belgium and abroad.”
Marc Subirats, Partner at Nina Capital: “At Nina Capital, we invest in need-driven health tech companies with international ambitions, and moveUP ticks all the boxes. The solution delivers meaningful clinical and value outcomes, reinventing healthcare with the help of technology. We will support the team of moveUP to navigate the complex landscape of healthcare stakeholders in Spain, Europe and beyond.”
Jo Dumortier, CEO of CAREvolution: “At CAREvolution, we believe that health is an investment. That is why we support initiatives that have a positive impact on the quality and cost structure of our health system, while improving patient experience. moveUP perfectly fits this philosophy. Their solution contributes to reaching better patient outcomes after orthopaedic and bariatric surgery. We look forward to seeing its impact in other therapeutic areas.”
Jean Van Nuwenborg, Managing Partner at Qbic: “We are proud to be part of the further growth and development of moveUP. It has been exciting to see the amazing progress the company has made since its foundation and we are happy to join the syndicate to support this company to which two of our fund partners (AZ Maria Middelares and VUB) have been and will be contributing meaningfully going forward.”